SEQUENCE LISTING

<110> Soligenix, Inc.
Donini, Oreola
Rozek, Annett
Lee, Jackson
North, John
Abrams, Michael

<120> Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis

<130> 502.223WO

<140> PCT/US14/50516
<141> 2014-08-11

<150> 61/877767
<151> 2013-09-13

<160> 92

<170> PatentIn version 3.5

<210> 1
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Immunological Peptide

<400> 1

Lys Ser Arg Ile Val Pro
1 5

<210> 2
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is equal to Acetylated K

<400> 2

Xaa Ser Arg Ile Val Pro
1 5

<210> 3
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 3

Ser Arg Ile Val Pro Ala
1 5

<210> 4
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 4

Ser Arg Ile Val Ala
1 5

<210> 5
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 5

Arg Ile Val Pro Ala
1 5

<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 6

Lys Ile Val Pro Ala
1 5

<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is equal to D-Amino Acid of Ala

<400> 7

Arg Ile Val Pro Xaa
1 5

<210> 8
<211> 4

<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 8

Arg Val Pro Ala
1

<210> 9
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 9

Arg Ile Pro Ala
1

<210> 10
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is equal to Ala-OH

<400> 10

Arg Ile Val Pro Xaa
1 5

<210> 11
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 11

Arg Ala Val Pro Ala
1 5

<210> 12
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 12

Arg Arg Ile Val Pro Ala
1 5

<210> 13
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 13

Arg Lys Val Pro Ala
1 5

<210> 14
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 14

Arg Ile Val Pro Lys
1 5

<210> 15
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 15

Arg Pro Val Pro Ala
1 5

<210> 16
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 16

Arg Ile Pro Pro Ala
1 5

<210> 17
<211> 5
<212> PRT
<213> Artificial Sequence

<220>

<223> IMMUNOLOGICAL PEPTIDE

<400> 17

Arg Ile Val Pro Pro
1 5

<210> 18
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 18

Arg Ile Val Pro Gly Gly Ala
1 5

<210> 19
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 19

Gly Gly Ile Val Pro Ala
1 5

<210> 20
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 20

Gly Ile Val Pro Ala
1 5

<210> 21
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 21

Ala Gly Val Pro Ala
1 5

<210> 22
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE

<400>  22

Arg Ile Val Pro Gly
1               5


<210>  23
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE

<400>  23

Arg Ile Val Pro Ser
1               5


<210>  24
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE

<400>  24

Arg Ile Val Pro Leu
1               5


<210>  25
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE

<400>  25

Arg His Val Pro Ala
1               5


<210>  26
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE

<400>  26

Arg Ile Pro Val Ala
1               5


<210>  27
<211>  5

<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 27

Arg Val Ile Pro Ala
1 5

<210> 28
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 28

Arg Ile Ile Pro Ala
1 5

<210> 29
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 29

Ala Val Pro Ile Arg
1 5

<210> 30
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 30

Ala Pro Val Ile Arg
1 5

<210> 31
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 31

Arg Ile Val Pro Ala
1 5

<210> 32
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(7)
<223> cyclic peptide

<400> 32

Cys Arg Ile Val Pro Ala Cys
1 5

<210> 33
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is equal to I with an NMe backbone

<400> 33

Arg Xaa Val Pro Ala
1 5

<210> 34
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is equal to A with an N-methylated backbone

<400> 34

Arg Ile Val Pro Xaa
1 5

<210> 35
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 35

Arg Ile Val Pro Phe
1 5

<210> 36
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is equal to Citrulline

<400> 36

Xaa Ile Val Pro Ala
1 5

<210> 37
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 37

Arg Leu Val Pro Ala
1 5

<210> 38
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 38

His Ile Val Pro Ala
1 5

<210> 39
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 39

Ile Arg Arg Val Pro Ala
1 5

<210> 40
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 40

Ala Arg Val Pro Ala
1 5

<210> 41
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 41

Ile Arg Val Pro Ala
1 5

<210> 42
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is equal to Ornithine

<400> 42

Xaa Ile Val Pro Ala
1 5

<210> 43
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 43

Ser Ile Val Pro Ala
1 5

<210> 44
<211> 13
<212> PRT
<213> Artificial Sequence

<220>

<223> IMMUNOLOGICAL PEPTIDE

<400> 44

Val Ser Ile Ile Lys Pro Ala Arg Val Pro Ser Leu Leu
1 5 10

<210> 45
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 45

Lys Pro Ala Arg Val Pro Ser
1 5

<210> 46
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 46

Arg Val Pro Ser Leu Leu
1 5

<210> 47
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 47

Lys Pro Arg Ala Val Pro
1 5

<210> 48
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 48

Pro Ala Arg Val Pro
1 5

<210> 49
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE

<400>  49

Ile Arg Val Pro
1


<210>  50
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE

<400>  50

Arg Val Pro Ser
1


<210>  51
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE

<400>  51

Arg Val Pro
1


<210>  52
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE

<400>  52

Pro Ser Val Pro Gly Ser
1               5


<210>  53
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE

<400>  53

Gly Leu Lys His Pro Ser
1               5


<210>  54
<211>  11

<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 54

Arg Ile Val Pro Ala Ile Pro Val Ser Leu Leu
1 5 10

<210> 55
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is selected from the group consisting of K, H, R, S, T, O, Cit, Hci, Dab, Dpr, or glycine based compounds with basic functional groups substituted on the N-terminal, hSer, Val (betaOH)

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is selected from the group consisting of V, I, K, P, and H

<400> 55

Xaa Xaa Pro
1

<210> 56
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is selected from the group consisting of K, H, R, S, T, O, Cit, Hci, Dab, Dpr, or glycine based compounds with basic functional groups substituted on the N-terminal, hSer, Val (betaOH)

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is selected from the group consisting of A, I, L, V, K, P, G, H, R, S, O, Dab, Dpr, Cit, Hci, Abu, Nva, Nle and where Xaa can be N-methylated

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa is selected from the group consisting of I, V, P

<400> 56

Xaa Xaa Xaa Pro
1

<210> 57
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is selected from the group consisting of S, P, I, R, C, T, L, V, A, G, K, H, R, O, C, M and F

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is selected from the group consisting of K, H, R, S, T, O, Cit, Hci, Dab, Dpr, or glycine based compounds with basic functional groups substituted on the N-terminal, hSer, Val (betaOH)

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa is selected from the group consisting of A, I, L, V, K, P, G, H, R, S, O, Dab, Dpr, Cit, Hci, Abu, Nva, Nle and where Xaa can be N-methylated

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is selected from the group consisting of I, V, P

<400> 57

Xaa Xaa Xaa Xaa Pro
1 5

<210> 58
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is selected from the group consisting of K, H, R, S, T, O, Cit, Hci, Dab, Dpr, or glycine based compounds with basic functional groups substituted on the N-terminal, hSer, Val (betaOH)

<220>
<221> MISC_FEATURE
<222> (2)..(2)

<223> Xaa is selected from the group consisting of A, I, L, V, K, P, G, H, R, S, O, Dab, Dpr, Cit, Hci, Abu, Nva, Nle and where Xaa can be N-methylated

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa is selected from the group consisting of I, V, P

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is selected from the group consisting of A, A*, G, S, L, F, K, C, I, V, T, Y, R, H, O, and M, wherein A* denotes D amino acid of A

<400> 58

Xaa Xaa Xaa Pro Xaa
1 5

<210> 59
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is selected from the group consisting of K, I, R, H, O, L, V, A, and G

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is selected from the group consisting of S, P, R, T, H, K, O, L, V, A, G, S, I

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa is selected from the group consisting of K, H, R, S, T, O, Cit, Hci, Dab, Dpr, or glycine based compounds with basic functional groups substituted on the N-terminal, hSer, Val (betaOH)

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is selected from the group consisting of A, I, L, V, K, P, G, H, R, S, O, Dab, Dpr, Cit, Hci, Abu, Nva, Nle and where Xaa can be N-methylated

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is selected from the group consisting of I, V, P

<400> 59

Xaa Xaa Xaa Xaa Xaa Pro
1 5

<210> 60
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is selected from the group consisting of S, R, K, H, O, T, I, L, V, A, and G

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is selected from the group consisting of K, H, R, S, T, O, Cit, Hci, Dab, Dpr, or glycine based compounds with basic functional groups substituted on the N-terminal, hSer, Val (betaOH)

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa is selected from the group consisting of A, I, L, V, K, P, G, H, R, S, O, Dab, Dpr, Cit, Hci, Abu, Nva, Nle and where Xaa can be N-methylated

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is selected from the group consisting of I, V, P

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is selected from the group consisting of A, V, I, L, G, K, H, R, O, S, T, and F

<400> 60

Xaa Xaa Xaa Xaa Pro Xaa
1 5

<210> 61
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 61

Arg Ile Val Pro Ala Cys
1 5

<210> 62
<211> 4
<212> PRT
<213> Artificial Sequence

<220>

<223> IMMUNOLOGICAL PEPTIDE

<400> 62

Arg Arg Val Pro
1

<210> 63
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa is equal to A-NHOH

<400> 63

Arg Ile Val Pro Xaa
1 5

<210> 64
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 64

Arg Ile Val Pro Pro Ala
1 5

<210> 65
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 65

Arg Ile Gly Pro Ala
1 5

<210> 66
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (4)..(4)

<223>  Xaa is equal to Pip

<400>  66

Arg Ile Val Xaa Ala
1               5


<210>  67
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is equal to Thz

<400>  67

Arg Ile Val Xaa Ala
1               5


<210>  68
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is equal to Fpro

<400>  68

Arg Ile Val Xaa Ala
1               5


<210>  69
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is equal to Dhp

<400>  69

Arg Ile Val Xaa Ala
1               5

<210> 70
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 70

Arg Ile His Pro Ala
1 5

<210> 71
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 71

Arg Ile Trp Pro Ala
1 5

<210> 72
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 72

Arg Ile Val Pro Trp
1 5

<210> 73
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 73

Ser Pro Val Ile Arg His
1 5

<210> 74
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 74

Cys Pro Val Ile Arg His
1 5

<210> 75
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 75

Arg Ile Glu Pro Ala
1 5

<210> 76
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 76

Arg Ile Val Pro Glu
1 5

<210> 77
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 77

Arg Ile Val Pro His
1 5

<210> 78
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 78

Arg Ser Val Pro Ala
1 5

<210> 79
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 79

Glu Arg Ile Val Pro Ala Gly
1 5

<210> 80
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 80

Lys Val Ile Pro Ser
1 5

<210> 81
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 81

Lys Val Val Pro Ser
1 5

<210> 82
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 82

Lys Pro Arg Ser
1

<210> 83
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 83

Arg Ile Pro
1

<210> 84
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is equal to Orn

<400>  84

Xaa Val Pro
1


<210>  85
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE

<400>  85

Ser Val Pro
1


<210>  86
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE

<400>  86

Lys Val Pro
1


<210>  87
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE

<400>  87

Arg Arg Pro
1


<210>  88
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  IMMUNOLOGICAL PEPTIDE

<400>  88

Gly Val Pro
1

<210> 89
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<400> 89

Lys His Pro
1

<210> 90
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is equal to D-amino acid Tyr

<400> 90

Arg Ile Val Pro Ala Xaa
1 5

<210> 91
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa is equal to tBG, tert-butyl glycine

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is equal to tBG, tert-butyl glycine

<400> 91

Arg Xaa Val Lys Arg Xaa Val
1 5

<210> 92
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> IMMUNOLOGICAL PEPTIDE

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa is equal to mp2, 4-Amino-1-methyl-1H-pyrrole-2-carboxylic acid

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is equal to NH2

<400> 92

Arg Ile Val Xaa Ala Xaa
1 5